TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

By sjmartinez • June 30, 2023

Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2023 Jun 30. doi: 10.2217/fon-2023-0188. Epub ahead of print. PMID: 37387213.

Tags: antibody-drug conjugate (ADC), Cedars Sinai DoM, datopotamab deruxtecan (Dato-DXd), Hematology/Oncology, HR-positive/HER2-negative, inoperable breast cancer, metastatic breast cancer, Publications, Trophoblast cell surface antigen 2 (TROP2)

Related Posts

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]

What a pain in the back: etiology, diagnosis and future treatment directions for discogenic low back pain

Kaneda G, Zila L, Wechsler JT, Shafi K, Cheema K, Bae H, Kim SD, Tuchman A, Li D, Sheyn D. What a pain in the[...]

Oxidative stress-regulatory role of miR-10b-5p in the diabetic human cornea revealed through integrated multi-omics analysis

Zha D, Gamez J, Ebrahimi SM, Wang Y, Verma N, Poe AJ, White S, Shah R, Kramerov AA, Sawant OB, Santiskulvong C, Stotland AB, Wang[...]